Filtered By:
Drug: Docetaxel

This page shows you your search results in order of date. This is page number 11.

Order by Relevance | Date

Total 178 results found since Jan 2013.

Cooperative Treatment of Metastatic Breast Cancer Using Host–Guest Nanoplatform Coloaded with Docetaxel and siRNA
Conventional chemotherapy shows moderate efficiency against metastatic cancer since it targets only part of the mechanisms regulating tumor growth and metastasis. Here, gold nanorod (GNR)‐based host‐guest nanoplatforms loaded with docetaxel (DTX) and small interfering RNA (siRNA)‐p65 (referred to as DTX‐loaded GNR (GDTX)/p65) for chemo‐, RNA interference (RNAi), and photothermal ablation (PTA) cooperative treatment of metastatic breast cancer are reported. To prepare the nanoplatform, GNRs are first coated with cyclodextrin (CD)‐grafted polyethylenimine (PEI) and then loaded with DTX and siRNA through host–gu...
Source: Small - December 10, 2015 Category: Nanotechnology Authors: Dangge Wang, Tingting Wang, Zhiai Xu, Haijun Yu, Bing Feng, Junying Zhang, Chengyue Guo, Qi Yin, Zhiwen Zhang, Yaping Li Tags: Full Paper Source Type: research

The α7-nicotinic acetylcholine receptor mediates the sensitivity of gastric cancer cells to taxanes
Abstract Gastric cancer is difficult to cure because most patients are diagnosed at an advanced disease stage. Systemic chemotherapy remains an important therapy for gastric cancer, but both progression-free survival and disease-free survival associated with various combination regimens are limited because of refractoriness and chemoresistance. Accumulating evidence has revealed that the homomeric α7-nicotinic acetylcholine receptor (A7-nAChR) promotes human gastric cancer by driving cancer cell proliferation, migration, and metastasis. Therefore, A7-nAChR may serve as a potential therapeutic target for gastric c...
Source: Tumor Biology - October 25, 2015 Category: Cancer & Oncology Source Type: research

Abstract 4678: A novel nuclear transporter for androgen receptor and AR-variant-7 in castration resistant prostate cancer: Ideal therapeutic target
Conclusions: We identified novel (i) transporter of AR and (ii) approach for treating CRPC in men.Citation Format: Aijaz Parray, Hifzur R. Siddique, Alyssa Langfald, Pooja Singh, Mikihiko Naito, Robert Matusik, Ingo Schmitz, Shahriar Koochekpour, Badrinath R. Konety, Mohammad Saleem. A novel nuclear transporter for androgen receptor and AR-variant-7 in castration resistant prostate cancer: Ideal therapeutic target. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 4678. ...
Source: Cancer Research - August 2, 2015 Category: Cancer & Oncology Authors: Parray, A., Siddique, H. R., Langfald, A., Singh, P., Naito, M., Matusik, R., Schmitz, I., Koochekpour, S., Konety, B. R., Saleem, M. Tags: Endocrinology Source Type: research

Abstract 3948: Identification of a new therapeutic target in prostate cancer from siRNA screening in Docetaxel-resistant cells
Conclusion: We identified a new chaperone harbouring an enzymatic activity which could be a relevant therapeutic target in chemoresistant CRPC. We are now focusing on the identification of a specific inhibitor in order to validate the role of this target in two Docetaxel-resistant prostate cancer mice models established within the laboratory.Citation Format: Marine Garrido, Nicolas J-p Martin, Catherine Gaudin, Elaine Del Nery, Jacques Camonis, Franck Perez, Stéphanie Lerondel, Alain Le Pape, Karim Fizazi, Anne Chauchereau. Identification of a new therapeutic target in prostate cancer from siRNA screening in Docetaxel-res...
Source: Cancer Research - August 2, 2015 Category: Cancer & Oncology Authors: Garrido, M., Martin, N. J.-p., Gaudin, C., Del Nery, E., Camonis, J., Perez, F., Lerondel, S., Le Pape, A., Fizazi, K., Chauchereau, A. Tags: Molecular and Cellular Biology Source Type: research

Abstract 409: Docetaxel induced-JNK2/PHD1 signaling pathway increases cell death in cancer cells under hypoxia through the degradation of HIF-1{alpha}
In this study, we investigated the molecular mechanism underlying the docetaxel-induced degradation of HIF-1α and cell death in cancer cell under hypoxia. Pretreatment of docetaxel increased the polyubiquitination and proteasome mediated-degradation of HIF-1α and cell death in cancer cells under hypoxia. Under hypoxia, pharmacological inhibitors or siRNAs for PHD1 (prolyl hydroxylase 1) effectively prevented HIF-1α degradation and cancer cell death through inhibiting docetaxel-mediated activation of PHD1. In addition, siRNA-mediated knockdown of JNK2 blocked docetaxel-induced degradation of HIF-1α and cancer cell death...
Source: Cancer Research - August 2, 2015 Category: Cancer & Oncology Authors: Oh, E.-T., Song, M.-J., Lee, H., Choi, Y.-J., Park, H. J. Tags: Tumor Biology Source Type: research

Abstract 1724: Integrated functional RNAi screening and structural genomics identify inverse co-modulators of TP53 family and NF-{kappa}B transitional activation as potential therapeutic targets in head and neck squamous cell carcinoma
Head and neck squamous cell carcinoma (HNSCC) is the 6th most common cancer worldwide with a 50-60% mortality rate. Deregulation of p53 family members in HNSCC occurs in over 90% of cases, preventing transcription of growth arrest and apoptosis genes. Conversely, members of the NF-κB/REL family are aberrantly activated in about ∼70% of cases, and drive expression of pro-proliferation, inflammation, angiogenesis, and therapeutic resistance genes. The function of different TP53 and NF-κB family members are inversely modulated within two major subsets of HNSCC, suggesting that common molecules and pathways coordinate this...
Source: Cancer Research - August 2, 2015 Category: Cancer & Oncology Authors: Saleh, A., Cornelius, S., Martin, S., Ormanoglu, P., Cheng, H., Das, R., Yang, X., Chen, Z., Van Waes, C. Tags: Experimental and Molecular Therapeutics Source Type: research

Abstract 730: The role of ZEB1/ZEB2 and {beta}III-tubulin in mediating docetaxel-resistant prostate cancer
Docetaxel therapy is the gold standard treatment for advanced castrate-resistant prostate cancer (CRPC). However, patients either do not respond or develop resistance over time. Transcriptomic and proteomic analysis of docetaxel-resistant prostate cancer sub-lines developed by our group revealed multiple mechanisms of resistance in line with advanced disease, including over-expression of anti-apoptotic proteins and alterations of NF-KB activation. The sub-lines also demonstrated a coordinated loss and gain of epithelial and mesenchymal markers respectively; a process characteristic of Epithelial-Mesenchymal Transition (EMT...
Source: Cancer Research - August 2, 2015 Category: Cancer & Oncology Authors: Hanrahan, K., Prencipe, M., Bugler, J., Murphy, L., O'Neill, A., Watson, R. W. Tags: Experimental and Molecular Therapeutics Source Type: research

Abstract 1064: RASSF10 suppresses colorectal cancer growth by activating p53 signaling and sensitizes colorectal cancer cell to docetaxel
RASSF10 has previously been reported to be frequently methylated in a number of malignancies. To understand the importance of RASSF10 inactivation in colorectal carcinogenesis, eight colorectal cancer cell lines, 89 cases of primary colorectal cancer and 5 cases of normal colorectal mucosa were examined. Methylation specific PCR, western blot, siRNA, gene expression array and xenograft mice were employed. The expression of RASSF10 was was regulated by promoter regional methylation in colorectal cancer cells. RASSF10 was methylated in 60.7% (54/89) of primary colorectal cancers and was positively associated with tumor stage (p
Source: Cancer Research - August 2, 2015 Category: Cancer & Oncology Authors: Guo, J., Yang, Y., , Linghu, E., Zhan, Q., Brock, M. V., Herman, J. G., Zhang, B., Guo, M. Tags: Molecular and Cellular Biology Source Type: research

Abstract 16: Combination simvastatin and metformin induces G1-phase cell cycle arrest and Ripk1- and Ripk3-dependent necroptosis in C4-2B osseous metastatic castration-resistant prostate cancer cells
Castration-resistant prostate cancer (CRPC) cells acquire resistance to chemotherapy and apoptosis in part due to enhanced aerobic glycolysis and biomass production, known as Warburg effect. We previously demonstrated that combination simvastatin (SIM) and metformin (MET) ameliorates critical Warburg effect-related metabolic aberrations of C4-2B cells, synergistically and significantly decreases CRPC cell viability and metastatic properties, with minimal effect on normal prostate epithelial cells, and inhibits primary prostate tumor growth, metastasis, and biochemical failure in an orthotopic model of metastatic CRPC, more...
Source: Cancer Research - August 2, 2015 Category: Cancer & Oncology Authors: Babcook, M. A., Sramkoski, R. M., Fujioka, H., Daneshgari, F., Almasan, A., Shukla, S., Gupta, S. Tags: Molecular and Cellular Biology Source Type: research

Vascular endothelial growth factor directly stimulates tumour cell proliferation in non-small cell lung cancer.
Abstract Vascular endothelial growth factor (VEGF) is a key stimulator of physiological and pathological angiogenesis. VEGF signals primarily through VEGF receptor 2 (VEGFR2), a receptor tyrosine kinase whose expression is found predominantly on endothelial cells. The purpose of this study was to determine the role of VEGFR2 expression in NSCLC cells. NSCLC cells and tissue sections were stained for VEGFR2 expression by immunohistochemistry (IHC). Immunoblotting and ELISA were used to determine the activation and inhibition of VEGFR2 and its downstream signalling pathways. Five-day proliferation assays were carri...
Source: International Journal of Oncology - July 14, 2015 Category: Cancer & Oncology Authors: Devery AM, Wadekar R, Bokobza SM, Weber AM, Jiang Y, Ryan AJ Tags: Int J Oncol Source Type: research

The use of collagen-based scaffolds to simulate prostate cancer bone metastases with potential for evaluating delivery of nanoparticulate gene therapeutics.
In conclusion, development of a novel 3D cell culture model of prostate cancer bone metastasis has been initiated resulting, for the first time, in the successful delivery of gene therapeutics in a 3D in vitro model. Further enhancement of this model will help elucidate the pathogenesis of prostate cancer and also accelerate the design of effective therapies which can penetrate into the bone microenvironment for prostate cancer therapy. PMID: 26196533 [PubMed - as supplied by publisher]
Source: Biomaterials - July 14, 2015 Category: Materials Science Authors: Fitzgerald KA, Guo J, Tierney EG, Curtin CM, Malhotra M, Darcy R, O'Brien FJ, O'Driscoll CM Tags: Biomaterials Source Type: research

GLIPR1-ΔTM synergizes with docetaxel in cell death and suppresses resistance to docetaxel in prostate cancer cells
Conclusions: Our data suggested that addition of GLIPR1-ΔTM treatment in PCa cells increases the efficacy of docetaxel and may inhibit the emergence of drug resistance; potentially permitting a decrease of docetaxel dose for patients with mCRPC eliminating its systemic toxicities.
Source: Molecular Cancer - June 19, 2015 Category: Cancer & Oncology Authors: Styliani KaranikaTheodoros KarantanosShinji KurosakaJianxiang WangTakahiro HirayamaGuang YangSanghee ParkAlexei GolstovRyuta TanimotoLikun LiTimothy Thompson Source Type: research

Clinical significance of glycoprotein nonmetastatic B and its association with HER2 in breast cancer
Abstract Glycoprotein nonmetastatic B (GPNMB) is a potential oncogene that is particularly expressed in melanoma and breast cancer (BC). To clarify its clinical significance in BC, we measured serum GPNMB in vivo and investigated its cross talk with human epidermal growth factor 2 (HER2). GPNMB was expressed in four of six breast cell lines (SK‐BR‐3, BT‐474, MDA‐MD‐231, and MDA‐MD‐157), two of six colorectal cell lines, and two of four gastric cancer (GC) cell lines. We established a GPNMB quantification system using enzyme‐linked immunosorbent assay (ELISA) for these cell lines. We measured serum GPNMB in...
Source: Cancer Medicine - June 16, 2015 Category: Cancer & Oncology Authors: Masako Kanematsu, Manabu Futamura, Masafumi Takata, Siqin Gaowa, Atsuko Yamada, Kasumi Morimitsu, Akemi Morikawa, Ryutaro Mori, Hideaki Hara, Kazuhiro Yoshida Tags: Original Research Source Type: research

Role of ribophorin II in the response to anticancer drugs in gastric cancer cell lines.
Authors: Yuan TM, Liang RY, Chueh PJ, Chuang SM Abstract The identification of prognostic markers and establishing their value as therapeutic targets improves therapeutic efficacy against human cancers. Ribophorin II (RPN2) has been demonstrated to be a prognostic marker of human cancer, including breast and pancreatic cancers. The present study aimed to evaluate RPN2 expression in gastric cancer and to examine the possible correlation between RPN2 expression and the response of cells to clinical anticancer drugs, which has received little research attention at present. The gastric cancer AGS, TMC-1, SNU-1, TMK-1, ...
Source: Oncology Letters - June 4, 2015 Category: Cancer & Oncology Tags: Oncol Lett Source Type: research

Abstract P5-05-11: Growth hormone receptor silencing sensitizes triple negative breast cancer cells to chemotherapy
In this study we investigated the impact of GHR silencing in TNBC cells and further analyzed the possible mechanisms associated with GHR silencing induced sensitization. GHR was silenced using small interfering RNAs in metastatic breast cancer cells MDA MB 231 and MDA MB 468. Molecular analyses were performed to determine apoptosis, cytotoxicity, colony formation, invasion and migration in GHR knockdown cells. Silencing of GHR induced cytotoxicity and apoptosis in TNBC cells. Migratory and invasive potentials were drastically reduced in GHR silenced cells. Moreover, epithelial to mesenchymal transition markers were signifi...
Source: Cancer Research - April 30, 2015 Category: Cancer & Oncology Authors: Arumugam, A., Subramani, R., Nandy, S., Lopez-Valdez, R., Lakshmanaswamy, R. Tags: Poster Session Abstracts Source Type: research